Mustafa Ahmed, MD
Cardiovascular Disease · Gainesville, FLNPI 1730397886
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,543 of the $4,169 with a category attached, or 61.0%. 13 manufacturers reported payments, led by Medtronic at 36.7% of the total. Reporting peaked in 2022 at $1,573 and has fallen 81.1% since, to $298 in 2025.
Across 49 payments — averaging $85.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Modernatx, Inc.$805
- Abbott$540
- Biotronik Inc.$350
- Abiomed$322
- Biotronik NRO, Inc.$144
- plus $476 from 7 others
Across 82 payments — averaging $4480.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$177K
- Procyrion, Inc.$73K
- Modernatx, Inc.$54K
- E.r. Squibb & Sons, L.L.C.$43K
- Abbott$21K
What the payments were for
- Speaking & faculty fees$3508%
- Travel & lodging$1,27631%
- Food & beverage$2,54361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 14 | $1,532 |
| Modernatx, Inc. | 8 | $805 |
| Abbott | 8 | $540 |
| Biotronik Inc. | 1 | $350 |
| Abiomed | 3 | $322 |
| Biotronik NRO, Inc. | 1 | $144 |
| Corcept Therapeutics | 6 | $139 |
| Boston Scientific | 1 | $125 |
| AstraZeneca | 1 | $124 |
| Nuwellis, Inc. | 1 | $27 |
| Procyrion, Inc. | 2 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Cvrx, Inc. | 2 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,169 in reported general payments places this provider in the 60th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 55 | $64,738 |
| JardianceEmpagliflozin | 51 | $38,716 |
| EliquisApixaban | 15 | $16,560 |
| Ranolazine ErRanolazine | 19 | $1,493 |
| Metoprolol Succinate | 55 | $624 |
| Bumetanide | 25 | $602 |
| Spironolactone | 68 | $401 |
| Carvedilol | 36 | $323 |
| Lisinopril | 22 | $85 |
| Rosuvastatin Calcium | 17 | $60 |
| Losartan Potassium | 16 | $45 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Gainesville
- Juan ArandaGainesville$212K
- Keith MarchGainesville$176K
- Ann TongGainesville$160K
- Carlos Alviar RestrepoGainesville$104K
- Michael KorenGainesville$97K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.